With a gain of more than 531% over the last 12 months, shares of Viking Therapeutics (NASDAQ: VKTX) are a hot commodity, to say the least. And as of early November, there's one more big green flag ...

Similar adverse events as those seen with other GLP-1 receptor agonists were reported. The Company is also evaluating an oral tablet formulation of VK2735 (ClinicalTrials.gov Identifier: NCT05203237).

AstraZeneca’s new obesity pill, licensed from China’s Eccogene last year, has shown initial promise in early-stage trials.

While expected and seen as largely incremental, Jefferies analyst Peter Welford in a Tuesday note to investors said the detailed data for three early-stage assets support moving them into Phase IIb ...

Shares of Viking Therapeutics (NASDAQ: VKTX) fell on Monday, Nov. 4, despite some encouraging new data. Over the weekend, the ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Viking Therapeutics’ GLP-1 pill candidate for treating obesity showed promise in its latest trial results, the clinical-stage ...

Viking Therapeutics' weight loss drug VK2735 may challenge Novo Nordisk and Eli Lilly's dominance in the obesity drug space ...

Viking Therapeutics shares climbed 9% on Monday after the drug developer's oral obesity treatment helped reduce body weight ...

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Viking Therapeutics (VKTX – Research ...

Viking Therapeutics shares rose Monday morning before reversing course and declining after reporting the latest results from ...

Viking Therapeutics stock is volatile Monday after the pharma company released positive data for its weight-loss drug. Here's ...